+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Statins Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 210 Pages
  • July 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 5924997
The global statins market size is likely to be valued at US$ 15.5 Bn in 2025 and is estimated to reach US$ 21 Bn by 2032, expanding at a CAGR of 4.43% during the forecast period 2025-2032. Statins, primarily used to lower cholesterol levels and reduce cardiovascular disease risks, have become a critical component in preventive cardiology. With an increasing prevalence of obesity, heart disease, and aging populations worldwide, the demand for effective lipid-lowering agents like statins continues to grow.

Statins Market - Report Scope:

The statins market encompasses a broad range of cholesterol-lowering drugs prescribed for managing cardiovascular diseases, obesity, and inflammatory conditions. These drugs inhibit the enzyme HMG-CoA reductase, reducing cholesterol production in the liver. Growing awareness of cardiovascular health, improved diagnostic rates, and proactive treatment regimens are contributing to the steady growth of this market. Additionally, expanding access to healthcare and statin therapy in developing countries further fuels demand.

Key Market Growth Drivers:

The rising incidence of cardiovascular disorders, obesity, and related metabolic syndromes is a primary factor driving statins market growth. Increasing adoption of sedentary lifestyles, coupled with poor dietary habits, has amplified the risk of hypercholesterolemia globally. Government healthcare initiatives and campaigns promoting preventive cardiac care have also accelerated statin prescriptions. Additionally, expanding health insurance coverage in both developed and emerging economies is making cholesterol-lowering treatments more accessible.

Market Restraints:

Despite the widespread use of statins, certain limitations could hinder market expansion. These include growing concerns over the side effects associated with long-term statin use, such as muscle pain, liver dysfunction, and increased risk of diabetes. Moreover, the expiration of patents for blockbuster statin drugs has led to price erosion due to generic competition. Patient non-compliance and misinformation about statin therapy also remain challenges in achieving optimal market penetration.

Market Opportunities:

Emerging markets present lucrative opportunities for the statins industry, particularly in Asia Pacific and Latin America, where the burden of cardiovascular disease is rising rapidly. Advancements in drug delivery technologies and the development of combination therapies with statins offer new growth avenues. The increasing focus on personalized medicine and precision cardiovascular treatment could also stimulate innovation in the statins segment. Furthermore, strategic collaborations between pharmaceutical companies and healthcare providers are enhancing awareness and accessibility of statin-based treatments.

Regional Outlook:

North America dominates the statins market due to high cardiovascular disease prevalence, robust healthcare infrastructure, and widespread access to prescription medication. Europe follows closely, driven by aging demographics and public health initiatives. Asia Pacific is anticipated to witness the fastest growth, spurred by urbanization, dietary changes, and healthcare investments across countries like China and India. Latin America and the Middle East & Africa regions are gradually increasing their market share due to improved healthcare access and awareness campaigns.

Leading Companies:

Leading companies in the global statins market, such as Pfizer Inc., Merck & Co., Inc., and Novartis AG, continue to invest in clinical research, generic statin formulations, and market expansion strategies. Companies like Centrient Pharmaceuticals Netherlands B.V., Biocon, and Aurobindo Pharma USA are strengthening their positions through cost-effective manufacturing and supply chain capabilities. Partnerships, acquisitions, and innovative marketing campaigns remain key to staying competitive in this moderately consolidated market.

Companies Covered in This Report:

  • Pfizer Inc.
  • Centrient Pharmaceuticals Netherlands B.V.
  • CMP Pharma, Inc.
  • AstraZeneca
  • Salerno Pharma
  • Kowa Pharmaceuticals America, Inc.
  • Medicure Pharma
  • Covis Pharma
  • Novartis AG
  • Teva Pharmaceuticals USA, Inc.
  • Lupin
  • AdvaCare Pharma®
  • Arlak Corazon
  • Merck & Co., Inc.
  • CTX Lifesciences
  • Biofield Pharma
  • Organon group of companies
  • Taj Pharmaceuticals Limited
  • Aurobindo Pharma USA
  • Biocon

Market Segmentation:

By Drug Class:

  • Atorvastatins
  • Fluvastatins
  • Lovastatins
  • Pravastatins
  • Simvastatins
  • Others

By Therapeutic Treatment:

  • Obesity
  • Cardiovascular Disorders
  • Inflammatory Disorders
  • Others

By End User:

  • Hospitals
  • Clinics
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Statins Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Production Output and Trade Statistics, 2019-2024
3.1. Global Statins Production Output, by Region, Value (US$ Bn) and Volume, 2019-2024
3.1.1. North America
3.1.2. Europe
3.1.3. Asia Pacific
3.1.4. Latin America
3.1.5. Middle East and Africa
4. Price Analysis, 2019-2024
4.1. Global Average Price Analysis by Drug Class, 2019-2024
4.2. Prominent Factor Affecting Statins Prices
4.3. Global Average Price Analysis by Region
5. Global Statins Market Outlook, 2019-2032
5.1. Global Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2019-2032
5.1.1. Key Highlights
5.1.1.1. Astrovastatins
5.1.1.2. Fluvastatins
5.1.1.3. Lovastatins
5.1.1.4. Pravastatins
5.1.1.5. Simvastatins
5.1.1.6. Others
5.2. Global Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
5.2.1. Key Highlights
5.2.1.1. Cardiovascular Disorders
5.2.1.2. Obesity
5.2.1.3. Inflammatory Disorders
5.2.1.4. Others
5.3. Global Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2019-2032
5.3.1. Key Highlights
5.3.1.1. Hospitals
5.3.1.2. Clinics
5.4. Global Statins Market Outlook, by Region, Value (US$ Bn) and Volume, 2019-2032
5.4.1. Key Highlights
5.4.1.1. North America
5.4.1.2. Europe
5.4.1.3. Asia Pacific
5.4.1.4. Latin America
5.4.1.5. Middle East & Africa
6. North America Statins Market Outlook, 2019-2032
6.1. North America Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2019-2032
6.1.1. Key Highlights
6.1.1.1. Astrovastatins
6.1.1.2. Fluvastatins
6.1.1.3. Lovastatins
6.1.1.4. Pravastatins
6.1.1.5. Simvastatins
6.1.1.6. Others
6.2. North America Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
6.2.1. Key Highlights
6.2.1.1. Cardiovascular Disorders
6.2.1.2. Obesity
6.2.1.3. Inflammatory Disorders
6.2.1.4. Others
6.3. North America Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2019-2032
6.3.1. Key Highlights
6.3.1.1. Hospitals
6.3.1.2. Clinics
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. North America Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2019-2032
6.4.1. Key Highlights
6.4.1.1. U.S. Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
6.4.1.2. U.S. Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
6.4.1.3. U.S. Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
6.4.1.4. Canada Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
6.4.1.5. Canada Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
6.4.1.6. Canada Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Europe Statins Market Outlook, 2019-2032
7.1. Europe Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2019-2032
7.1.1. Key Highlights
7.1.1.1. Astrovastatins
7.1.1.2. Fluvastatins
7.1.1.3. Lovastatins
7.1.1.4. Pravastatins
7.1.1.5. Simvastatins
7.1.1.6. Others
7.2. Europe Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
7.2.1. Key Highlights
7.2.1.1. Cardiovascular Disorders
7.2.1.2. Obesity
7.2.1.3. Inflammatory Disorders
7.2.1.4. Others
7.3. Europe Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2019-2032
7.3.1. Key Highlights
7.3.1.1. Hospitals
7.3.1.2. Clinics
7.3.2. Attractiveness Analysis
7.4. Europe Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2019-2032
7.4.1. Key Highlights
7.4.1.1. Germany Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
7.4.1.2. Germany Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
7.4.1.3. Germany Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
7.4.1.4. U.K. Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
7.4.1.5. U.K. Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
7.4.1.6. U.K. Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
7.4.1.7. France Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
7.4.1.8. France Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
7.4.1.9. France Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
7.4.1.10. Italy Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
7.4.1.11. Italy Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
7.4.1.12. Italy Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
7.4.1.13. Turkey Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
7.4.1.14. Turkey Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
7.4.1.15. Turkey Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
7.4.1.16. Russia Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
7.4.1.17. Russia Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
7.4.1.18. Russia Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
7.4.1.19. Rest of Europe Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
7.4.1.20. Rest of Europe Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
7.4.1.21. Rest of Europe Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Asia Pacific Statins Market Outlook, 2019-2032
8.1. Asia Pacific Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2019-2032
8.1.1. Key Highlights
8.1.1.1. Astrovastatins
8.1.1.2. Fluvastatins
8.1.1.3. Lovastatins
8.1.1.4. Pravastatins
8.1.1.5. Simvastatins
8.1.1.6. Others
8.2. Asia Pacific Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
8.2.1. Key Highlights
8.2.1.1. Cardiovascular Disorders
8.2.1.2. Obesity
8.2.1.3. Inflammatory Disorders
8.2.1.4. Others
8.3. Asia Pacific Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2019-2032
8.3.1. Key Highlights
8.3.1.1. Hospitals
8.3.1.2. Clinics
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Asia Pacific Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2019-2032
8.4.1. Key Highlights
8.4.1.1. China Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
8.4.1.2. China Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
8.4.1.3. China Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
8.4.1.4. Japan Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
8.4.1.5. Japan Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
8.4.1.6. Japan Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
8.4.1.7. South Korea Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
8.4.1.8. South Korea Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
8.4.1.9. South Korea Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
8.4.1.10. India Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
8.4.1.11. India Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
8.4.1.12. India Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
8.4.1.13. Southeast Asia Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
8.4.1.14. Southeast Asia Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
8.4.1.15. Southeast Asia Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
8.4.1.16. Rest of Asia Pacific Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
8.4.1.17. Rest of Asia Pacific Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
8.4.1.18. Rest of Asia Pacific Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Latin America Statins Market Outlook, 2019-2032
9.1. Latin America Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2019-2032
9.1.1. Key Highlights
9.1.1.1. Astrovastatins
9.1.1.2. Fluvastatins
9.1.1.3. Lovastatins
9.1.1.4. Pravastatins
9.1.1.5. Simvastatins
9.1.1.6. Others
9.2. Latin America Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
9.2.1. Key Highlights
9.2.1.1. Cardiovascular Disorders
9.2.1.2. Obesity
9.2.1.3. Inflammatory Disorders
9.2.1.4. Others
9.3. Latin America Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2019-2032
9.3.1. Key Highlights
9.3.1.1. Hospitals
9.3.1.2. Clinics
9.3.2. BPS Analysis/Market Attractiveness Analysis
9.4. Latin America Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2019-2032
9.4.1. Key Highlights
9.4.1.1. Brazil Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
9.4.1.2. Brazil Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
9.4.1.3. Brazil Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
9.4.1.4. Mexico Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
9.4.1.5. Mexico Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
9.4.1.6. Mexico Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
9.4.1.7. Argentina Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
9.4.1.8. Argentina Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
9.4.1.9. Argentina Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
9.4.1.10. Rest of Latin America Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
9.4.1.11. Rest of Latin America Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
9.4.1.12. Rest of Latin America Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
9.4.2. BPS Analysis/Market Attractiveness Analysis
10. Middle East & Africa Statins Market Outlook, 2019-2032
10.1. Middle East & Africa Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2019-2032
10.1.1. Key Highlights
10.1.1.1. Astrovastatins
10.1.1.2. Fluvastatins
10.1.1.3. Lovastatins
10.1.1.4. Pravastatins
10.1.1.5. Simvastatins
10.1.1.6. Others
10.2. Middle East & Africa Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
10.2.1. Key Highlights
10.2.1.1. Cardiovascular Disorders
10.2.1.2. Obesity
10.2.1.3. Inflammatory Disorders
10.2.1.4. Others
10.3. Middle East & Africa Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2019-2032
10.3.1. Key Highlights
10.3.1.1. Hospitals
10.3.1.2. Clinics
10.3.2. BPS Analysis/Market Attractiveness Analysis
10.4. Middle East & Africa Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2019-2032
10.4.1. Key Highlights
10.4.1.1. GCC Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
10.4.1.2. GCC Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
10.4.1.3. GCC Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
10.4.1.4. South Africa Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
10.4.1.5. South Africa Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
10.4.1.6. South Africa Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
10.4.1.7. Egypt Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
10.4.1.8. Egypt Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
10.4.1.9. Egypt Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
10.4.1.10. Nigeria Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
10.4.1.11. Nigeria Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
10.4.1.12. Nigeria Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
10.4.1.13. Rest of Middle East & Africa Statins Market by Drug Class, Value (US$ Bn) and Volume, 2019-2032
10.4.1.14. Rest of Middle East & Africa Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2019-2032
10.4.1.15. Rest of Middle East & Africa Statins Market by End User, Value (US$ Bn) and Volume, 2019-2032
10.4.2. BPS Analysis/Market Attractiveness Analysis
11. Competitive Landscape
11.1. By End User vs by Therapeutic Treatment Heatmap
11.2. Company Market Share Analysis, 2025
11.3. Competitive Dashboard
11.4. Company Profiles
11.4.1. Pfizer Inc.
11.4.1.1. Company Overview
11.4.1.2. Product Portfolio
11.4.1.3. Financial Overview
11.4.1.4. Business Strategies and Development
11.4.2. AstraZeneca plc
11.4.2.1. Company Overview
11.4.2.2. Product Portfolio
11.4.2.3. Financial Overview
11.4.2.4. Business Strategies and Development
11.4.3. Novartis International AG
11.4.3.1. Company Overview
11.4.3.2. Product Portfolio
11.4.3.3. Financial Overview
11.4.3.4. Business Strategies and Development
11.4.4. GlaxoSmithKline plc
11.4.4.1. Company Overview
11.4.4.2. Product Portfolio
11.4.4.3. Financial Overview
11.4.4.4. Business Strategies and Development
11.4.5. Merck & Co., Inc.
11.4.5.1. Company Overview
11.4.5.2. Product Portfolio
11.4.5.3. Financial Overview
11.4.5.4. Business Strategies and Development
11.4.6. Biocon
11.4.6.1. Company Overview
11.4.6.2. Product Portfolio
11.4.6.3. Financial Overview
11.4.6.4. Business Strategies and Development
11.4.7. Aurobindo Pharma Ltd
11.4.7.1. Company Overview
11.4.7.2. Product Portfolio
11.4.7.3. Financial Overview
11.4.7.4. Business Strategies and Development
11.4.8. Concord Biotech
11.4.8.1. Company Overview
11.4.8.2. Product Portfolio
11.4.8.3. Financial Overview
11.4.8.4. Business Strategies and Development
12. Appendix
12.1. Research Methodology
12.2. Report Assumptions
12.3. Acronyms and Abbreviations

Companies Mentioned

  • Pfizer Inc.
  • Centrient Pharmaceuticals Netherlands B.V.
  • CMP Pharma, Inc.
  • AstraZeneca
  • Salerno Pharma
  • Kowa Pharmaceuticals America, Inc.
  • Medicure Pharma
  • Covis Pharma
  • Novartis AG
  • Teva Pharmaceuticals USA, Inc.
  • Lupin
  • AdvaCare Pharma®
  • Arlak Corazon
  • Merck & Co., Inc.
  • CTX Lifesciences
  • Biofield Pharma
  • Organon group of companies
  • Taj Pharmaceuticals Limited
  • Aurobindo Pharma USA
  • Biocon